ClinicalTrials.gg
Active, not recruitingNCT06062537TEC-CAREUpdated Apr 13, 2026

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

An observational study in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Intergroupe Francophone du Myelome · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome — 1 open to participants now, 4 under way, 2 of them phase 3. Multiple Myeloma · Intergroupe Francophone du Myelome.

Started
2023
the only one that year
Observational
3 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, this one is the only one that started in 2023, is one of 3 observational ones, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, or all of them as a file.
02

Study summary

200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria.

This is a multicenter, prospective, observational study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • teclistamab
  • refractory multiple myeloma
  • real word evidence study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

French adult patient relapsed and refractory multiple myeloma receving teclistamab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose)

Exclusion criteria

Exclusion Criteria:

  • Patients alive at the start of the study who did not receive study information or who objected to the collection of data
  • Patients who received teclistamab as part of an interventional clinical trial
  • Patients who are initiating teclistamab as part of a current interventional clinical trial
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. overall response rate (ORR) of teclistamab according to IMWG criteria

    ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.

    Time frame: 6 months

  2. overall response rate (ORR) of teclistamab according to IMWG criteria

    ORR is defined as the proportion of subjects who achieve a PR or better according to IMWG criteria.

    Time frame: 24 months

Secondary outcomes

  1. Effectiveness of teclistamab

    Progression Free Survival 1 and 2 (PFS)

    Time frame: 24 months

  2. Effectiveness of teclistamab

    Overall survival (OS)

    Time frame: 24 months

  3. Effectiveness of teclistamab

    Duration of overall response (DOR)

    Time frame: 24 months

  4. Effectiveness of teclistamab

    Response rate (sCR, CR, VGPR, PR)

    Time frame: 24 months

  5. Effectiveness of teclistamab

    Time to best response

    Time frame: 24 months

  6. Effectiveness of teclistamab

    Time to next treatment (TTNT)

    Time frame: 24 months

  7. Effectiveness of teclistamab

    Time to discontinuation (TTD)

    Time frame: 24 months

  8. Adverse events of interest

    ICANS, CSR and infections

    Time frame: 24 months

  9. Conditions of use

    Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during step-up dosing phase

    Time frame: 1 month

  10. Conditions of use

    Patients' profiles (demographics characteristics and medical history) \- Injection facilities and schedules during follow up phase

    Time frame: 24 months

07

Study locations

31 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 33. This study's planned 39 months is below that.

Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 2, 2023
StartActual
Sep 19, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06062537
Lead sponsor
Intergroupe Francophone du Myelome
Collaborators
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Sep 19, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion